Ayako Shiraishi

Chiyoda, 1010065, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.

Journal: BMC psychiatry

Published: February 12, 2021

JunB plays a crucial role in development of regulatory T cells by promoting IL-2 signaling.

JunB plays a crucial role in development of regulatory T cells by promoting IL-2 signaling.

Journal: Mucosal immunology

Published: October 14, 2018

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.

Journal: Alzheimer's research & therapy

Published: March 29, 2018

Effects of eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats.

Effects of eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats.

Journal: Journal of bone and mineral metabolism

Published: August 19, 2014

Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate

Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: June 13, 2014

Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.

Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.

Journal: The Journal of steroid biochemistry and molecular biology

Published: July 31, 2013

Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.

Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.

Journal: Bone

Published: September 07, 2012

Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.

Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.

Journal: Bone

Published: December 12, 2011

The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.

The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.

Journal: BMC musculoskeletal disorders

Published: September 10, 2008

Calcium supplementation does not reproduce the pharmacological efficacy of alfacalcidol for the treatment of osteoporosis in rats.

Calcium supplementation does not reproduce the pharmacological efficacy of alfacalcidol for the treatment of osteoporosis in rats.

Journal: Calcified tissue international

Published: January 18, 2005

Showing 1-10 of 10

Last Updated: 09/26/2026